Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma

Autor: Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. Van Not, Djura Piersma, Rozemarijn S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. Van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. Van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters

Publikováno v: Cancers, 15(2):409. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 15(2). MDPI
Cancers, 15, 2
de Meza, M M, Blokx, W A M, Bonenkamp, J J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma : A Propensity-Matched Outcome Analysis ', Cancers, vol. 15, no. 2, 409 . https://doi.org/10.3390/cancers15020409
Cancers; Volume 15; Issue 2; Pages: 409
Cancers, 15

Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of stage III melanoma in patients with BRAF V600 mutations in clinical trials. However, little is known about how these therapies compare to each other i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3601b23aa21c729b0a455facbd7e5ade
https://doi.org/10.3390/cancers15020409

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

Autor: Olivier J. van Not, Willeke A.M. Blokx, Alfons J.M. van den Eertwegh, Melissa M. de Meza, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A.M. van der Veldt, Marye J. Boers-Sonderen, Anne M.L. Jansen, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk

Publikováno v: JCO Precision Oncology, 6:e2200018. American Society of Clinical Oncology
JCO Precision Oncology, 6
JCO Precision Oncology, 6:e2200018. AMER SOC CLINICAL ONCOLOGY

PURPOSE Little is known about the effect of specific gene mutations on efficacy of immune checkpoint inhibitors in patients with advanced melanoma. MATERIALS AND METHODS All patients with advanced melanoma treated with first-line anti–PD-1 or ipili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a14d11d0fa70f6a29c2366447ae5ff
https://doi.org/10.1200/PO.22.00018

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients

Autor: Michel W.J.M. Wouters, Marion Stevense, Ellen Kapiteijn, Christian U. Blank, Karijn P M Suijkerbuijk, Astrid Aplonia Maria Van Der Veldt, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Alfonsus J. M. van den Eertwegh, Gerard Vreugdenhil, Maureen J.B. Aarts, Liesbeth C. de Wreede, Jesper van Breeschoten, Erik W. van Zwet, John B. A. G. Haanen, Jan Willem B. de Groot, Franchette W P J van den Berkmortel, Marye Boers-Sonderen, Doranne L. Hilarius

Publikováno v: Cancers, 13(20):5077. MDPI AG
Cancers, 13, 20
van Breeschoten, J, van den Eertwegh, A J M, de Wreede, L C, Hilarius, D L, van Zwet, E W, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-sonderen, M J, Suijkerbuijk, K P M & Wouters, M W J M 2021, ' Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients : Nationwide quality assurance in the netherlands ', Cancers, vol. 13, no. 20, 5077 . https://doi.org/10.3390/cancers13205077
Cancers, 13(20):5077. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 13, Iss 5077, p 5077 (2021)
Cancers, 13(20). MDPI
Cancers
Volume 13
Issue 20
Cancers, 13

Simple Summary: The survival of advanced melanoma patients has improved significantly over the last decade due to the introduction of new systemic therapies. It is unknown whether survival outcomes of advanced melanoma patients differ between melanom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d369fca07c88bdc71e6f5d5567757c91
https://hdl.handle.net/11370/144a687b-1f76-44fd-acca-1d9813cd82c3

Dutch advanced melanoma care in times of COVID-19

Autor: G. Vreugdenhil, Willeke A. M. Blokx, Mieke J. Aarts, Karijn P M Suijkerbuijk, Marion Stevense, Marye J Boers-Sonderen, F.W.P.J. van den Berkmortel, Ellen Kapiteijn, A.A.M. Van der Veldt, Michel W.J.M. Wouters, C. Blank, J.W.B. de Groot, Geke A. P. Hospers, J. Van Breeschoten, O. J. Van Not, D Piersma, J.B.A.G. Haanen, Doranne L. Hilarius, A.J.M. van den Eertwegh, R van Rijn

Publikováno v: Journal of Clinical Oncology, 39(15). AMER SOC CLINICAL ONCOLOGY

e21502 Background: The COVID-19 pandemic COVID had a severe impact on medical care in The Netherlands. So far, few studies have investigated the influence of COVID-19 on advanced melanoma care nationwide. This study aims to investigate the impact of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e45ee65897a96d3b0e9b6d511c639f4
https://research.rug.nl/en/publications/22b245f3-28a8-4039-aa99-37e7b3bf7343